Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 517 publications
When adipose tissue talks to the liver through galectin-3.
Journal: Metabolism: clinical and experimental
Published: August 31, 2026
Incidence and predictors of distal symmetrical polyneuropathy in prediabetes: A 24-month prospective cohort study.
Journal: Diabetes research and clinical practice
Published: May 03, 2026
Letter: Integrating Noninvasive Liver Indices into Risk Stratification of Myocardial Infarction With Non-Obstructive Coronary Arteries.
Journal: Angiology
Published: April 11, 2026
GLP-1 receptor agonists and atrial fibrillation: Chronotropy, atrial substrate, and cardiometabolic mechanisms.
Journal: Metabolism: clinical and experimental
Published: March 19, 2026
Repurposing GLP-1 receptor agonists and SGLT-2 inhibitors in neurodegeneration and metabolically at-risk populations: Myth or reality? An overview of randomized clinical trials.
Journal: Diabetes research and clinical practice
Published: March 13, 2026
Mediterranean diet: definitions, health effects and metabolic pathways - evidence and future directions.
Journal: Metabolism: clinical and experimental
Published: March 12, 2026
Patient-specific deep offline artificial pancreas for blood glucose regulation in type 1 diabetes.
Journal: Smart health (Amsterdam, Netherlands)
Published: March 02, 2026
Gallein targets AMPK in AgRP neurons: A new anti-obesity hypothalamic strategy?
Journal: Metabolism: clinical and experimental
Published: February 17, 2026
Nephrin is produced in visceral adipose tissue in humans and associates with insulin resistance.
Journal: Diabetes research and clinical practice
Published: February 10, 2026
ALG-055009 in non-cirrhotic adults with metabolic dysfunction-associated steatohepatitis (HERALD): a randomised, double-blind, placebo-controlled, phase 2a trial.
Journal: The lancet. Gastroenterology & hepatology
Published: January 08, 2026
Effects of liraglutide treatment for 35-days on total and regional fat, lean, and bone mass, and on the Myostatin-Activin-Follistatin-IGF-1 axes: a secondary analysis of a randomized placebo-controlled crossover study.
Journal: Diabetes research and clinical practice
Published: December 28, 2025
Effects of liraglutide treatment for 35-days on total and regional fat free, lean, and bone mass, and on the Myostatin-Activin-Follistatin-IGF-1 axes: a secondary analysis of a randomized placebo-controlled crossover study.
Journal: Diabetes research and clinical practice
Published: December 28, 2025
Last Updated: 09/26/2026